Summary

For kidney cancer, TCGA will create a reference genome, against which new patients will be compared, for both clear cell and papillary cancer types. According to the NIH, the initial objectives of TCGA for kidney cancer are:

• Identify unique patterns of genomic changes that divide clear cell and papillary carcinoma tumors into subgroups.
• Identify genomic differences that distinguish tumors across gender, race, or ethnicity.
• Determine if specific patterns of genomic changes are connected to tumor recurrence after therapy.

Research and Publications

Please contact us at help@cancerimagingarchive.net if you have any questions about these policies.

TCGA-KIRC Marker Paper and Image Source Sites (ISS)

Imaging Source Site (ISS) Groups will be populated and governed by participants from institutions that have provided imaging data to the archive for a given cancer type. Modeled after TCGA analysis groups, ISS groups are given the opportunity to publish a marker paper for a given cancer type per TCGA Publication Guidelines. This opportunity will generate increased participation in building these multi-institutional data sets as they become an open community resource. Current TCGA-KIRC source sites include:

• Memorial Sloan-Kettering Cancer Center
• University of Pittsburgh / UPMC
• Mayo
• NCI Urologic Oncology Branch
• UNC

Please contact Dr. Oguz Akin (akino@mskcc.org) if you have scientific questions for TCGA-KIRC ISS or are interested in collaborating with their group.

References

The following links contain publications from the main TCGA project as well as their posted publication guidelines:

• TCGA Publications
• TCGA Publication Guidelines

2nd Annual TCGA Symposium

• Adverse Outcomes in Clear Cell Renal Cell Carcinoma With Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2
  • Ari Hakimi, MD, Memorial Sloan-Kettering Cancer Center
  • Video | Slides
• TCGA Clear Cell Renal Cell Carcinoma Project
  • Chad J. Creighton, PhD, Baylor College of Medicine
  • Video | Slides